Drugs / Boswellia
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03149081 | Aug 2017 → Apr 2024 | breast cancer | Medical University of South Carolina | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04800107 | Jan 2021 → Dec 2025 | tinnitus | Henry Ford Health System | Withdrawn | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06466538 Comparator | Jun 2022 → Jul 2024 | — | Mansoura University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boswellia | “The treatment group will be provided with a supply of capsules containing 500 mg of curcumin-phosphatidylcholine combined with 250 mg of boswellia-phosphatidylcholine, which...” NCT04800107 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Ayurveda (Indian traditional medicine practice) used Boswellia for the treatment of gastrointestinal diseases such as diarrhea, constipation, flatulence and vomiting.” NCT06466538 ↗ |
| Route | Oral | “oral administration of Boswellia” NCT03149081 ↗ |